29 May 2019 11:07
Verona Pharma plc
PDMR Dealing
May 29, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, announces that, on May 28, 2019, Kayt Morgan, spouse of Mr. Piers Morgan, CFO of the Company, purchased 33,802 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 59 pence per Ordinary Share and a total purchase price of £19,954.18. Following the acquisition, Mr. Morgan will have a beneficial interest in the Company of 147,009 Ordinary Shares, representing 0.14% of the Company's issued share capital.
This purchase brings the total purchases by Mr. and Mrs. Morgan during the past few months to over £52,000 and follows the purchases made by the Company's Chairman, Dr. David Ebsworth, in March totaling approximately £50,000.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name
| Kayt Morgan |
2 | Reason for the notification | |
a) | Position/status
| Spouse (PCA) of Piers Morgan, Chief Financial Officer |
b) | Initial notification/Amendment
| Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Verona Pharma plc |
b) | LEI
| 213800EVI6O6J3TIAL06
|
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5 pence each GB00BYW2KH80 | ||||
b) | Nature of the transaction
| Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A
| ||||
e) | Date of the transaction | 28 May 2019 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
For further information, please contact:
Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer Victoria Stewart, Director of Communications | info@veronapharma.com |
N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 3283 4200
|
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance) Mia Gardner (Corporate Broking) |